Introduction {#Sec1}
============

Urinary incontinence is a common condition in women with annual costs of nearly 10 billion euros in both direct and indirect costs in Europe \[[@CR1]\]. Most of these women suffer from stress urinary incontinence (SUI) \[[@CR2], [@CR3]\]. The costs for diagnosis, treatment, and follow-up of patients with SUI differ among countries. Insight into these costs is useful for cost-effectiveness research into new treatment modalities and for clinical guideline development. A clear international overview of these cost estimates is currently lacking. Therefore, information on costs should be gathered from health economic research data. Economic data from cost-effectiveness studies shows great variability \[[@CR4]\], which prevents the reliable use of these data.

Although variation among countries and hospitals with respect to relative prices is expected, there are other factors that cause variation. Units of resource use are often not clearly described and defined, introducing great variability in cost estimates. Moreover, lack of transparency in the costing methodology and procedures used in health economic evaluation research hamper insight into the composition of costs. In the field of female pelvic floor medicine and reconstructive surgery, Rawlings and Zimmern demonstrated that cost estimates for unit measures vary considerably. Costs were commonly not itemized, not all relevant costs were reported, and indirect costs were inconsistent and not always considered \[[@CR5]\]. Furthermore, de Soarez et al. demonstrated that the methodology and quality of health economic evaluations is often inadequate, and that costs cannot be transferred internationally \[[@CR6]\]. Other authors showed considerable heterogeneity in cost estimations for the prevention, detection, and treatment of various diseases \[[@CR7], [@CR8]\].

There is a demand for an international overview of cost estimates for SUI and insight into the variation affecting these estimates \[[@CR9]\]. As outlined above, cost estimates generated by health economic evaluation research cannot be used without caution. This review is aimed at providing an overview of cost estimates for different components in the diagnosis, treatment, and follow-up of SUI. Furthermore, we aimed to assess variation in cost estimates for SUI, and explore factors causing this variation. We also offer a preliminary recommendation for the incorporation of economic data from economic research at a national level into multinational cost-effectiveness analysis.

This overview facilitates researchers performing cost-effectiveness research and clinical guideline development in the field of SUI.

Materials and methods {#Sec2}
=====================

We conducted a systematic review of health economic evaluation studies that addressed costs reported in comparative analyses of diagnostic procedures or treatment modalities for women with SUI.

Search {#Sec3}
------

The search strategy was developed in collaboration with a medical librarian (JD). A scoping search based on reference checking and citation analysis ("cited by" and citing articles) was conducted. Results from this search were used to derive key concepts and to identify relevant articles that had to be retrieved by the systematic search.

The systematic search was conducted in July 2017 in the Ovid MEDLINE & other non-indexed materials and Ovid Embase bibliographic databases. The National Health Service Economic Evaluation Database (NHS-EED) filter for identifying economic evaluations and the McMaster sensitive therapy filter were combined with a search strategy for SUI. In addition, the WHO ICTRP search portal was searched to identify relevant trials. The retrieved trial numbers were included in the systematic search strategy. No additional limits were applied. Full details of the search strategy can be found in the appendix.

Selection of articles {#Sec4}
---------------------

References for studies that were identified using the search strategy were imported in Covidence. BCO, MD, and SZ separately and independently screened titles and abstracts for relevance using the inclusion and exclusion criteria stated below.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

We included studies on adult women with SUI that complied with the following criteria:Screening or diagnostic testing, conservative interventions (i.e., medication or pelvic floor muscle training) or surgery, or use of medical devices or other management of SUIComparative studies (at least two interventions)Full economic evaluations (taking into account both effectiveness, i.e., health outcomes and/or quality of life, and costs)Primary study design, either empirical (clinical cohort or trial) or model-based (for instance, decision tree or Markov model)Published in any scientific journal from peer-reviewed journals between January 1995 and July 2017

Exclusion criteria were:Studies performed in elderly patients or in nursing homesOpinion pieces, short communications and conference proceedingsCost-of-illness studiesCost-consequence analysesReviews

Selection of full-text articles {#Sec6}
-------------------------------

After screening titles and abstracts, full article texts were evaluated for relevance. In case of discrepancies, BCO and SEZ discussed the contents of the article until consensus was reached. If consensus was not reached, the article was presented to a third objective reviewer. All full-text articles were retrieved and used for this review.

Data extraction {#Sec7}
---------------

A data extraction sheet was developed to extract key bibliographic characteristics and relevant data for health economic evaluation studies \[[@CR10]\]. We extracted general data (author, year, country, setting, type of intervention evaluated, costing characteristics, etc.), and type of economic analysis.

All reported cost estimates and associated units costs were extracted and categorized according to the following rubrics: admissions, adverse events, consultant, diagnostics, incontinence material, laundry, medical equipment, medication, procedure, productivity, and travel \[[@CR11]\]. Within these rubrics, further classification was based on the level of aggregation, to allow meaningful comparisons. Costs were extracted and categorized according to the level of aggregation. A high level of aggregation incorporated surgical procedures that included all costs related to staff time, operating theater, surgical disposables, and hospital stay for recovery. A low level of aggregation included hourly costs of a gynecologist, surgeon or nurse; purchase costs of incontinence material, etc. We therefore classified and presented the results for various cost estimates by classifying them as having a high, medium or low level of aggregation, and medium- or low-level cost estimates were organized and reported in the following rubrics: admissions to health care institutions, diagnostic procedures, health care providers, surgical procedures, or materials. For instance, within the rubric "consultations," the categories are general practitioner (GP), physiotherapist, surgeon, anesthesiologist, nurse visits, and hourly wages for GPs, surgeons, nurses, etc.

Indexation and country adjustment of cost estimates and unit costs {#Sec8}
------------------------------------------------------------------

To allow valid and meaningful comparisons of unit cost estimates within and between countries, a common price level is required for each country in addition to the reported price year, so unit costs can be converted. Reported cost estimates were converted to 2017 Euros at the Dutch price level, adjusted for price year using the consumer price index for each country of July of the reported year and the year 2017, and for purchasing power using OECD comparative purchasing power parities \[[@CR12], [@CR13]\]. If no price year had been reported, July of the year before the publication year was assumed to be the price year. When the price year ranged over 2 years, which we have seen in the literature search, for instance 2000--2001, July of the first year was assumed to be the price year. In one article mentioning unforeseen hospitalization costs as a percentage of the total population, costs per day for one person were recalculated.

Determining transferability of costs {#Sec9}
------------------------------------

Transferability of costs was determined using the criteria of Fukuda et al. These authors describe four levels of transferability, depending on the extent to which components of costs and data for costs are reported. The method of calculating unit costs is also taken into account \[[@CR8]\].

The following levels of transferability are taken into account, as cited from Fukuda et al. \[[@CR8]\]:AAll components of costs were described and data for both quantity and unit price of resources were reported for each componentBAll components of costs were described and data for costs in each component were reported. This included studies that used graphical presentations of the aforementioned dataCAll components of costs were described, but data for costs in each component were not reportedDOnly the scope of costing was described, but the components of costs were not described

The following standards were used to apply the abovementioned categories to our data:AQualitative economic data of quantities and unit prices for each component for which costs were describedBEconomic data of quantities and unit prices where costs were weighted or averagedCData in categories where no separate components or units are describedDOverall cost data (=costs for a procedure without further specification of components)

Determining the quality of costing methodology {#Sec10}
----------------------------------------------

Costing methodologies are categorized according to the following quality criteria, also cited from Fukuda \[[@CR8]\]:IMicro costing or quasi-micro costingIIUse of relative value unitsIIIUse of ratio of costs to chargesIVUnmodified charge dataVUnknown

Reporting of cost estimates and unit costs {#Sec11}
------------------------------------------

Adjusted cost estimates of hospital admissions (=cost of a hospital bed per day) were presented graphically to illustrate the variability in reported prices for the same cost estimate within and between countries (see Fig. [2](#Fig2){ref-type="fig"}). Costs were presented as provided in the literature (cost per day) or costs per 8 h if hourly wages or wages for multiple days were presented. In addition, for the most common unit of health care use in the treatment of SUI---hospital admission (day admission for inpatient or outpatient procedure)---more detailed reporting of (variation in) unit costs was provided, including the source and variation of the cost estimates.

An overview of costs for tension-free vaginal tape (TVT) and urodynamic testing was also given.

Results {#Sec12}
=======

Selection of articles {#Sec13}
---------------------

Of the 1,980 articles identified using our search strategy (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}), a total of 37 articles were selected and included in this review (Fig. [1](#Fig1){ref-type="fig"}). Reasons for exclusion were, for example, not an economic evaluation, but cost outcome, unsuitable study design (study protocol), unsuitable patient population (no SUI, but mixed UI, gender), and price year before 1995 (could not be adjusted). As we selected articles using the online platform Covidence, agreement could not be calculated. A summary of all the studies included is presented in Table [3](#Tab3){ref-type="table"}.Table 1Search strategy in MEDLINEOvid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE® \< 1946 to Present \> Search date: 20 July 2017 (initial search: 25 November 2015)NumberSearchesResults1Economics/or exp. "costs and cost analysis"/or Economics, Dental/or exp. economics, hospital/or Economics, Medical/or Economics, Nursing/or Economics, Pharmaceutical/261,3372(economic\$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\$ or (expenditure\$ not energy) or "value for money" or budget\$).ab,ti.666,61931 or 2782,4504(((energy or oxygen) adj cost) or (metabolic adj cost) or ((energy or oxygen) adj expenditure)).ti,ab.25,88253 not 4776,5326(letter or editorial or historical article).pt.1,756,19675 not 6743,4638exp animals/not humans4,442,32397 not 8698,66810(bmj or "cochrane database of systematic reviews" or "health technology assessment winchester england").jn.87,780119 not 10 \[NHS-EED filter MEDLINE, consulted 20,151,104\]693,01112clinical trial.mp.672,21313clinical trial.pt.523,45314random:.mp. or tu.xs.5,075,31715or/12--14 \[McMaster sensitive therapy filter\]5,242,69316exp enuresis/or exp. urinary incontinence/34,56917(((urin\* or bladder) adj3 incontin\*) or encopresis or enures\* or ((urin\* or bladder) adj2 control) or (urin\* adj2 (leak\* or hold\*)) or icq or interstim).ab,kf,ti.34,5781816 or 17 \[urinary incontinence\]48,6461911 and 15 and 1861520(NCT02316275 or ISRCTN57746448 or NTR3783 or NCT01239836 or NTR1871 or NCT00814749 or NTR1248 or NCT00611026 or NTR1181 or NCT00509730 or NCT00498888 or NCT00444925 or NCT00425100 or ACTRN12605000755639 or NCT00200031 or ISRCTN97769568).ab,kf,ti.621(MiniMo or VUSIS or "Value of Urodynamics Prior to Stress Incontinence Surgery").ab,kf,ti.1672220 or 21 \[relevant urinary incontinence trials\]1712319 or 2278424remove duplicates from 23738Table 2Search strategy in EmbaseEmbase Classic + Embase \< 1947 to 2017 July 19 \> '. Ovid interface.\
Search date: 20 July 2017 (initial search: 25 November 2015)NumberSearchesResults1Health Economics/or exp. Economic Evaluation/or exp. Health Care Cost/ or pharmacoeconomics/469,1732(econom\$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\$ or (expenditure\$ not energy) or (value adj2 money) or budget\$).ab,ti.876,67031 or 21,084,6234(letter or editorial or note).pt.2,207,77753 not 4995,5416((metabolic adj cost) or ((energy or oxygen) adj cost) or ((energy or oxygen) adj expenditure)).ti,ab.31,41375 not 6988,9678animal/or exp. animal experiment/or nonhuman/7,360,4259(rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.5,915,466108 or 98,581,28611exp human/or human experiment/18,874,7751210 not (10 and 11)6,515,262137 not 12903,17314(0959--8146 or 1469-493X or 1366--5278).is.76,948151756--1833.en.24,2481614 or 1594,2601713 not 16897,27318conference abstract.pt.2,614,3761917 not 18 \[NHS-EED filter for Embase\]764,88720random:.tw.1,229,84421clinical trial:.mp.1,480,00822exp health care quality/2,545,17823or/20--22 \[McMaster Embase sensitive therapy filter\]4,306,19124exp urine incontinence/67,41025(((urin\* or bladder) adj3 incontin\*) or encopresis or enures\* or ((urin\* or bladder) adj2 control) or (urin\* adj2 (leak\* or hold\*)) or icq or interstim).ab,kw,ti.53,4452624 or 25 \[urinary incontinence\]80,2812719 and 23 and 261,34328(NCT02316275 or ISRCTN57746448 or NTR3783 or NCT01239836 or NTR1871 or NCT00814749 or NTR1248 or NCT00611026 or NTR1181 or NCT00509730 or NCT00498888 or NCT00444925 or NCT00425100 or ACTRN12605000755639 or NCT00200031 or ISRCTN97769568).ab,kw,ti.829(MiniMo or VUSIS or "Value of Urodynamics Prior to Stress Incontinence Surgery").ab,kw,ti.493028 or 29 \[relevant urinary incontinence trials\]563127 or 301,39832remove duplicates from 311,367Fig. 1Flowchart. *Asterisk* studies included in this review come from the following countries: Australia, Bosnia-Herzegovina, China, Canada, Egypt, Finland, France, Ireland, Netherlands, Spain, Sweden, United Kingdom, United StatesTable 3Bibliographic, clinical, and methodological characteristics of studies included in this reviewReferencePublication yearCountryPrice yearCurrencySample sizeSettingInterventions comparedCost analysisCosting transferabilityCosting methodAlbers-Heitner et al. \[[@CR33]\]2012Netherlands2007Euros384General practiceCare as usual by GPs versus care by nurse specialistCUABIAnkardal et al. \[[@CR14]\]2007Sweden2003Euros714HospitalOpen Burch colposuspension, laparoscopic colposuspension and TVTCEAAIBoyers et al. \[[@CR15]\]2013UK2011Pounds137Secondary careSIMS (Ajust) versus SMUS (TVT-O)CUAAIBrunenberg et al. \[[@CR16]\]2006Netherlands2002Euros1000\*General practiceDuloxetine versus PFMTCEAAIDumville et al. \[[@CR17]\]2006UK2002--2003Pounds286Gynecological surgical centersOpen colposuspension versus laparoscopic colposuspensionCUAAIFoote et al. \[[@CR35]\]2007Australia1995Australian dollars205Pelvic floor unit, hospitalNurse continence advisor versus urogynecologistCUABIHana et al. \[[@CR18]\]2012Bosnia\*2007--2010/2011Euros60HospitalVaginoplasty versus TVT-OCBAAIJacklin et al. \[[@CR34]\]2010UK2007--2008PoundsHospitalTVT versus duloxetineCUABIKilonzo et al. \[[@CR19]\]2004Ireland2001Pounds?HospitalTVT versus other surgical proceduresCUAAIKobelt and Fianu-Jonasson \[[@CR20]\]2006France and Sweden2004Euros159HospitalNASHA/Dx gel versus TVTCUAAIKondo et al. \[[@CR38]\]2006Japan2005US dollars60HospitalTVT or pubovaginal slingCost comparisonDIVKumar et al. \[[@CR49]\]2017USA1998US dollars--HospitalSling versus BurchCUADIIIKung et al. \[[@CR21]\]1996Canada1994Canadian dollars62Tertiary referral practiceLaparoscopic versus abdominal BurchCEAAIKunkle et al. \[[@CR39]\]2015USA2013US dollars**--**HospitalBA versus MUSCUADIVLamb et al. \[[@CR22]\]2009UK2004--2005Pounds174Primary careGroup or individual physiotherapy sessionsCost comparisonAILier et al. \[[@CR44]\]2011Canada2007Canadian dollars194HospitalTOT versus TVTCUACILier et al. \[[@CR45]\]2016Canada2011Canadian dollars195HospitalTOT versus TVTCUACILo et al. \[[@CR23]\]2013Canada2010Canadian dollars18HospitalBurch colposuspension, laparoscopic two-team sling and TOTCost comparisonAIMaher et al. \[[@CR40]\]2005Australia1998Australian dollars45Tertiary referral practicePubovaginal sling versus transurethral MacroplastiqueCost-outcome descriptionDIVManca et al. \[[@CR24]\]2003UK\*1999--2000Pounds214HospitalTVT versus colposuspensionCUAAIMihaylova et al. \[[@CR25]\]2010UK2007Pounds1510Primary careDuloxetine, duloxetine + nonsurgical conservative treatment, nonsurgical conservative treatmentCUAAIMontesino-Semper et al. \[[@CR36]\]2013SpainEuros69Primary care and hospitalSurgical intervention (sling/mesh) versus therapeutic abstentionCost comparisonBIMoore et al. \[[@CR26]\]2003Australia1998Australian dollars110Tertiary referral centerNurse continence advisor therapy versus standard urogynecologist careCost-outcome descriptionAINorton et al. \[[@CR41]\]2016USA2014US dollars630Tertiary referral practiceOE versus OE plus UDSCost comparisonDIVPersson et al. \[[@CR27]\]2002Sweden1998?Euros79HospitalLaparoscopic colposuspension versus TVTCost comparisonAIRamsay et al. \[[@CR37]\]1996UK1995Pounds74HospitalInpatient versus outpatient continence programCost-outcome descriptionBIRichardson et al. \[[@CR46]\]2013USA2010US dollarsModelHospitalMUS versus abdominal sacrocolpopexyCUACIVRichardson et al. \[[@CR47]\]2014USA2012US dollarsModelPrimary care and hospitalConservative therapy (pessary or PFMT) versus MUSCUACIVSand et al. \[[@CR48]\]2013USA2012US dollarsModelHospitalCost effectiveness of five strategies for SUI patients in whom conservative treatment failedCost comparisonCIVSeklehner et al. \[[@CR43]\]2014USA2012US dollarsModelTertiary referral practiceRetropubic MUS versus TO MUSCUABIVSjӧstrӧm et al. \[[@CR28]\]2015Sweden2010Euros250Primary careTwo treatment programs (internet-based treatment program versus post) and no treatmentCUAAISjӧstrӧm et al. \[[@CR29]\]2017Sweden2013Euros123Primary careMobile app for treatment of SUICUAAISubak et al. \[[@CR30]\]2014USA2012Dollars491HospitalBurch versus fascial sling surgeryCost comparisonAIValpas et al. \[[@CR31]\]2006Finland2000Euros121HospitalTVT versus laparoscopic mesh colposuspensionCEAAIVermeulen et al. \[[@CR32]\]2016Netherlands2010Euros350General practicePro-active approach of diagnostics and treatment versus comparisonCUAAIVon Bargen and Patterson \[[@CR42]\]2015USA2012DollarsModelPrimary care and hospitalNonsurgical versus surgical treatmentsCUADIV*CUA* cost--utility analysis, *CEA* cost-effectiveness analysis

Data extraction {#Sec14}
---------------

Included studies reported a range of cost estimates, covering various health care activities relevant for diagnosis and treatment of SUI, with varying levels of aggregation or detail. Data were extracted and entered into an Excel sheet.

Costing transferability and methodology level {#Sec15}
---------------------------------------------

Table [4](#Tab4){ref-type="table"} shows the costing transferability and costing methodology of the articles included. As presented, most included articles score an A-I level on transferability and methodology \[[@CR14]--[@CR32]\]. This means that micro- or quasi-micro costing was applied and that all components of costs were described. The second largest categories were B-I and D-IV, in which use of relative units with all components and charge data with the scope of costing was given respectively. B-I means that relative data for all components have been given \[[@CR33]--[@CR37]\]. D-IV generally means that unmodified charge data for the entire procedure was given \[[@CR38]--[@CR42]\]. All other categories (i.e., BIV, CI, CIV, DIII) applied to only three of the included articles or fewer. Least represented categories were B-IV \[[@CR43]\], C-I \[[@CR44], [@CR45]\], C-IV \[[@CR46]--[@CR48]\], and D-III \[[@CR49]\].Table 4Costing transferability and costing methodology \[[@CR7], [@CR8]\]Costing methodologyIIIIIIIVVCosting transferabilityAAnkardalet al. \[[@CR14]\]Boyers et al. \[[@CR15]\]Brunenberg et al. \[[@CR16]\]Dumville et al. \[[@CR17]\]Hana et al. \[[@CR18]\]Kilonzo et al. \[[@CR19]Kobelt and Fianu-Jonasson \[[@CR20]Kung et al. \[[@CR21]\]Lamb et al. \[[@CR22]\]Lo et al. \[[@CR23]Manca et al. \[[@CR24]\]Mihaylova et al. \[[@CR25]\]Moore et al. \[[@CR26]\]Persson et al. \[[@CR27]\]Sjӧstrӧm et al. \[[@CR28]\]Sjӧstrӧm et al. \[[@CR29]\]Subak et al. \[[@CR30]\]Valpas et al. \[[@CR31]\]Vermeulen et al. \[[@CR32]BAlbers-Heitner et al. \[[@CR33]\]Jacklin et al. \[[@CR34]Foote et al. \[[@CR35]\]Montesino-Semper et al. \[[@CR36]\]Ramsay et al. \[[@CR37]\]Seklehner et al. \[[@CR43]\]CLier et al. \[[@CR44]\]Lier et al. \[[@CR45]\]Richardson et al. \[[@CR46]Richardson et al. \[[@CR47]Sand et al. \[[@CR48]\]DKumar et al. \[[@CR49]\]Kondo et al. \[[@CR38]\]Kunkle et al. \[[@CR39]\]Maher et al. \[[@CR40]\]Norton et al. \[[@CR41]von Bargen and Patterson \[[@CR42]\]

Exploration of reported cost estimates {#Sec16}
--------------------------------------

The costs of hospitalization in different countries and clinical departments were investigated.

Standardized unit costs per day of hospital stay varied considerably within and between countries (Fig. [2](#Fig2){ref-type="fig"}). Overall, unit costs for hospital admissions in gynecology ranged between 82 and 1292 Euros per day. The lowest estimates were reported for the UK, where prices varied between 82 and 518 Euros (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR15], [@CR17], [@CR22], [@CR24], [@CR37]\]; whereas the highest estimates were observed in the USA, namely 1,292 Euros per day \[[@CR43]\]. Hospitalization in a general ward was less expensive than in a urology department (median 208 versus 855 Euros) \[[@CR15], [@CR17], [@CR20], [@CR24], [@CR43]\]. Costs reported for staying in a gynecology department ranged from 82 Euros per day to 995 Euros per day \[[@CR14], [@CR35], [@CR20], [@CR23]--[@CR24], [@CR40], [@CR27], [@CR37], [@CR31]\]. Costs that were used for the descriptive analyses were derived from the studies included. These studies either used national sources \[[@CR14], [@CR15], [@CR17], [@CR20], [@CR22], [@CR23]--[@CR24], [@CR27], [@CR37], [@CR40]\], or unknown sources \[[@CR31], [@CR35], [@CR37], [@CR43]\].Fig. 2Standardized unit costs per day of hospitalization vary between and within countriesFig. 3Standardized unit costs per day of hospitalization day in the gynecology department vary between countries

Costs of gynecological consultation range from 30 Euros in France to 228 Euros per hour in the UK \[[@CR20], [@CR24]\]. The cost of a TVT device ranges from 431 Euros in Finland to 994 Euros in Canada \[[@CR31], [@CR44], [@CR45]\]. TVT surgery per minute costs range from 25 Euros in Finland to 82 Euros in Sweden \[[@CR27], [@CR31]\]. Total costs for TVT range from 1,224 Euros in Ireland to 5,809 Euros for inpatient care in France \[[@CR19], [@CR20]\].

Different units to express the costs of hospital stay were identified, including average cost per day \[[@CR14], [@CR17], [@CR20], [@CR24], [@CR27], [@CR31], [@CR35], [@CR37], [@CR40], [@CR43]\] or NHS cost day \[[@CR22]\]. Occasionally, cost per hour or cost per night was given \[[@CR15], [@CR23], [@CR31], [@CR43]\]. As none of these articles described the duration of a hospital day, we could not convert cost per hour/night to the more common unit of a full hospital admission day.

Figure [4](#Fig4){ref-type="fig"} shows the results of the TVT material given. Costs from the UK, Sweden and Finland were comparable, but costs from Canada were significantly higher.Fig. 4Standardized unit costs for tension-free vaginal tape equipment vary between countries

Figure [5](#Fig5){ref-type="fig"} shows the costs of urodynamic testing. Costs in Canada are significantly lower than in the UK, Sweden, and France.Fig. 5Standardized unit costs for urodynamic testing vary among countries

Discussion {#Sec17}
==========

We have assessed the variation in unit cost estimates that are reported in economic evaluation studies and have provided an overview of cost estimates for different components in the diagnosis, treatment, and follow-up of SUI. Our study suggests that for many commonly reported cost units in the field of SUI, the cost estimates vary widely among studies and among countries. In addition, reported costs are not commonly listed in detail. Our study provides evidence that variability in cost estimates results from differences in interventions and health care services among countries, and that sources used to derive costs and the way in which units are defined cause dissimilarities in costs.

Strengths and limitations {#Sec18}
-------------------------

Both a strength and limitation of our study is the focus on the clinical area of SUI. A clear clinical focus limits the range of interventions and health care services provided for this condition. On the other hand, this focus may limit generalizability, as we do not know whether such heterogeneity in cost estimates would be similar in other fields of medicine. Nevertheless, the costs of hospital admissions for instance, one of our main outcomes, is not necessarily based on the corresponding intervention.

Second, the classification criteria we used to define costing methodology and transferability could be debated. We applied the criteria used by Fukuda et al., which makes our methods consistent with earlier work \[[@CR8]\]. As these criteria are not very strictly defined and may be applied differently to cost components within a single study, this classification approach may not be optimal. On the other hand, a common framework to characterize and summarize studies in terms of costing methodology and/or transferability is currently lacking. The criteria of Fukuda et al. could contribute to such a framework.

Finally, we did not combine cost estimates to a pooled average. To our knowledge, few health economic studies in the field of gynecology have been published that systematically review cost estimates produced by health economic evaluation research \[[@CR50]\]. Therefore, there is no evidence that studies are consistent at reporting transparently, and transferable cost estimates are scarcely used. It is unclear whether unit costs within countries can be pooled to a national average cost estimate, and to what extent unit cost estimates can be generalized to other countries \[[@CR51], [@CR52]\]. Oppong et al. conducted a systematic review to evaluate health economic studies that were performed in multinational trials. The authors concluded that pooling of the outcomes was impossible because, for instance, studies did not use cost prices from all countries that participated in the specific trial \[[@CR53]\]. These findings underline the need for better pooling strategies when using cost estimates and unit cost estimates in clinical trials for each country enrolling patients in the trial. Given the large variety of reported cost estimates and different cost estimates or cost units, our data were not homogeneous enough to allow pooling. Therefore, this review has resulted into a more descriptive evaluation of the study results instead of providing pooled estimates for different levels of aggregation that are not necessarily directly linked to a specific intervention. In 1998, Schulman et al. presented a method to use cost estimates to calculate relative medical cost indices that could be used in cost estimates for multinational purposes \[[@CR54]\]. However, to allow generalization to similar settings or transfer to other countries, reported costs that are included in the model need to be consistent \[[@CR51], [@CR52]\]. Thus far, there is no best practice for reporting generalizable and transparent costs. As a guideline, the use of costing methodology and costing transferability as described in the methods of this article incorporating the definitions of Fukuda et al. should be utilized by researchers when establishing cost data \[[@CR8]\].

Transparent definition of costing units of health care use {#Sec19}
----------------------------------------------------------

The way in which units of resource use are currently reported introduces bias that can have a negative effect on the interpretation of costs from research studies. Although most of our included studies scored high in transferability, we did see that the taxonomy in definitions of units was often not transparent. For instance, although most articles describe hospital stay as mean costs per day, this is not particularized any further. For instance, hospital stay was defined as average cost per day \[[@CR14], [@CR17], [@CR20], [@CR24], [@CR27], [@CR31], [@CR35], [@CR37], [@CR40], [@CR43]\] or NHS cost per day \[[@CR22]\]. This terminology does not reveal what the cost units actually entail as no further description of a day has been given. Consequently, it is not clear whether all costs that have been included in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} are actually comparable. In these figures, no distinction is made between inpatient and outpatient care, type of anesthesia, type of treatment, and treatment duration. Therefore, the component hospital stay could vary depending on its source.

Moreno and Montesino have described the economic impact of an inpatient versus outpatient treatment of SUI \[[@CR11]\]. These authors describe all components of a hospital stay, including personnel costs, materials, medicines, laundry, etc. These specific costs are not generally mentioned in our included articles. Some articles do describe the separate units and most mention "hospital bed" as the unit to be costed, but it is unclear whether all separate units include the same components. The NHS calculates the cost of a hospital bed according to the treatments that are required for the average patient occupying that bed \[[@CR55]\]. In an editorial, Bryce Travers explains that the daily cost of a hospital bed depends on what support a particular patient needs in the patient's specific care pathway \[[@CR56]\]. However, this would make costing personalized and therefore perhaps more complex than previously thought. But, a guide such as that given by Moreno and Montesino that comprehensively explains different costing units in the diagnosis and treatment of SUI would improve transparency of costs and transferability of costs between settings and countries \[[@CR11]\].

Differences between countries {#Sec20}
-----------------------------

Standardized unit costs vary within and among countries. These differences in costs do not seem to be consistent and from our limited data we cannot determine whether the differences we observe are statistically relevant. What we do see is that variation within countries can be the result of reporting absolute versus relative unit cost estimates or the use of varying units for consultation costs, for instance, costs per hour, costs per visit, or costs per consultation. Moreover, outpatient and inpatient costs are both reported and also depend on whether the patient is admitted to a ward or gynecology department. Overall, we have not been able to identify a noteworthy pattern in the variation of unit cost estimates.

Implications: a recommendation for future economic evaluation studies {#Sec21}
---------------------------------------------------------------------

### Sources {#Sec22}

Most studies use national guidelines as a source for the price of the cost estimates. However, we also found studies that obtained the unit cost estimates by interviewing doctors, surveying hospitals or approximating costs from charges. Using different sources for deriving unit cost estimates is not necessarily wrong; Fukuda et al. describe that some costing methodologies are more accurate than others \[[@CR8]\]. However, national cost estimates and local charge data are not the same. Therefore, it should be the aim of researchers to use the highest possible source of estimates to produce meaningful results and to draw transparent and transferable conclusions. The best available evidence should be used for clinical decision-making \[[@CR57]\]. When costs are not based on the best available evidence, costs are not reliable. Therefore, as should be done when deriving evidence for the efficacy and safety of a treatment, deriving evidence on costs should also be done with great care.

### Transferability and costing method {#Sec23}

As a consequence of heterogeneity in studies reporting unit measures with associated costs, it is not possible to draw immediate conclusions with regard to the cost-effectiveness of new treatments. Especially when new treatments are studied, reported costs should entail all included unit measures and not only overall cost differences. Only then could the cost-effectiveness of the new treatment option---with care---be transferred and compared with the cost-effectiveness of other interventions for SUI. For accurate calculation of pooled cost estimates that are based on multiple evidence sources, the results of these sources need to be presented in a transparent and reproducible way \[[@CR9], [@CR58]--[@CR59]\].

### Transfer between countries {#Sec24}

In this review, differences among countries are accounted for using transparent methods to adjust cost estimates. Variation in economic estimates that are attributable to differences between countries seems of low significance \[[@CR58]\], but study outcomes are not generalizable when economic circumstances and differences in health systems across countries are not taken into account \[[@CR53]\]. In 1998, Schulman et al. presented a way of establishing cost estimates, "relative medical cost indices," that could be used as a method to transfer costs from one country to another \[[@CR54]\]. Such a method can unfortunately not be universally used throughout time: the model is susceptible to differences in discounting among countries, and the indices are therefore not fixed. Oppong et al. has given more information about differences among countries and how these affect generalizability. Oppong et al. propose that overcoming systematic differences due to economic circumstances and health systems and improving generalizability can be achieved by:Carefully selecting countries for inclusion in studiesUsing a checklist to overcome heterogeneityUse protocols on treatment patternsReporting costs from different perspectives Additionally, in the ISPOR recommendations from 2009, Drummond et al. suggest models that might be used to correct for differences among countries \[[@CR59]\].

Specific methodology has been used in our review to approximate differences between economic circumstances; however, this does not automatically accommodate differences in healthcare systems.

Conclusion {#Sec25}
==========

To facilitate insight into the variation of costs we presented an overview of a commonly used unit---hospital admission---and reported corresponding cost estimates. We also described the source of these costs and the way in which the cost estimate was calculated. Heterogeneity was observed in unit costs for most units; at both a more aggregated level (for instance a surgical procedure) and for units at a lower level of aggregation (for instance hourly wages for nurses or medical specialists). Heterogeneity in cost estimates is likely the consequence of sources used, actual cost differences among countries, lacking transparency in costing procedures or time-related factors \[[@CR7], [@CR8]\]. Ultimately, the results of our study imply that every research study that includes costs has to ascertain that the reported costs are valid and reliable. Consequently, these costs should be used with caution in cost-effectiveness studies.

Studies used varying taxonomy and definitions for estimated costs, and unit costs vary considerably between settings and countries. To minimize variation in unit costs, more uniform taxonomy definitions of units and cost analyses are required. Only then are cost estimates comparable or even transferable among countries and can be used in meta-analyses of cost-effectiveness studies.

Available cost-effectiveness outcomes should be interpreted with care, as reported cost estimates can be outdated, biased or unreliable. The methodology of economic evaluation research would benefit from quality standards as proposed in this review. Such quality standards are aimed reducing methodological heterogeneity and allow exploration and explanation of clinical heterogeneity in cost estimates. Available cost-effectiveness results are likely most valid for (or even limited to) particular health care contexts; more standardized methods, taxonomy, and definitions will enhance transferability to other contexts.

CEA

:   Cost-effectiveness analysis

SUI

:   Stress urinary incontinence

UI

:   Urinary incontinence
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